Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Vaginal Estrogenization in Postmenopausal Women

Menopause; ePub 2016 Nov 28; Lindau, et al

Higher vaginal estrogenization was prevalent across all age groups and with no decline in age compared to 1960s clinical data, according to a recent study that examined the prevalence and correlates of vaginal estrogenization in postmenopausal women in the US. Using a US national probability sample of 868 postmenopausal women aged 57 to 85 years, epithelial maturation value (MV) generated from self-collected vaginal specimens were calculated and the findings compared with historical clinical data. Researchers found:

  • In every age group, vaginal estrogenization was higher among postmenopausal nonusers of HT in the 2005-2006 US cohort than reported for the 1960s Canadian clinical cohort.
  • MV was also higher among women who used postmenopausal hormone therapy (HT) in the prior 12 months vs those who did not.
  • The strongest independent correlates were current HT use, obesity, and African American race.
  • Half of all women exhibit low vaginal estrogenization postmenopause.

Citation:

Lindau ST, Dude A, Gavrilova N, Hoffmann JN, Schumm PL, McClintock MK. Prevalence and correlates of vaginal estrogenization in postmenopausal women in the United States. [Published online ahead of print November 28, 2016]. Menopause. doi:10.1097/GME.0000000000000787.